HomeCompareIUGNF vs SPHD

IUGNF vs SPHD: Dividend Comparison 2026

IUGNF yields 1788.91% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IUGNF wins by $3531675981.98M in total portfolio value
10 years
IUGNF
IUGNF
● Live price
1788.91%
Share price
$0.11
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3531675982.01M
Annual income
$3,181,793,952,650,469.00
Full IUGNF calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — IUGNF vs SPHD

📍 IUGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIUGNFSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IUGNF + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IUGNF pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IUGNF
Annual income on $10K today (after 15% tax)
$152,057.25/yr
After 10yr DRIP, annual income (after tax)
$2,704,524,859,752,898.50/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, IUGNF beats the other by $2,704,524,859,752,416.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IUGNF + SPHD for your $10,000?

IUGNF: 50%SPHD: 50%
100% SPHD50/50100% IUGNF
Portfolio after 10yr
$1765837991.02M
Annual income
$1,590,896,976,325,518.20/yr
Blended yield
90.09%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IUGNF buys
0
SPHD buys
0
No recent congressional trades found for IUGNF or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIUGNFSPHD
Forward yield1788.91%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$3531675982.01M$26.5K
Annual income after 10y$3,181,793,952,650,469.00$567.37
Total dividends collected$3506616114.25M$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: IUGNF vs SPHD ($10,000, DRIP)

YearIUGNF PortfolioIUGNF Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$189,591$178,890.88$11,130$430.50+$178.5KIUGNF
2$3,372,589$3,169,726.93$12,357$447.82+$3.36MIUGNF
3$56,305,450$52,696,779.78$13,687$464.65+$56.29MIUGNF
4$882,465,426$822,218,594.62$15,126$480.98+$882.45MIUGNF
5$12,987,684,313$12,043,446,306.47$16,682$496.78+$12987.67MIUGNF
6$179,550,479,073$165,653,656,858.63$18,362$512.03+$179550.46MIUGNF
7$2,332,406,409,977$2,140,287,397,368.80$20,174$526.72+$2332406.39MIUGNF
8$28,479,672,886,997$25,983,998,028,321.59$22,127$540.84+$28479672.86MIUGNF
9$326,992,550,798,860$296,519,300,809,773.56$24,230$554.39+$326992550.77MIUGNF
10$3,531,675,982,005,250$3,181,793,952,650,469.00$26,493$567.37+$3531675981.98MIUGNF

IUGNF vs SPHD: Complete Analysis 2026

IUGNFStock

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.

Full IUGNF Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this IUGNF vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IUGNF vs SCHDIUGNF vs JEPIIUGNF vs OIUGNF vs KOIUGNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.